Factors that affect absorption behavior of cyclosporin A in gentamicin- induced acute renal failure in rats

Renal Failure

Volumn 22, Issue 2, 2000, Pages 181-194

  Shibata, Nobuhito ^a,b   Morimoto, Jun ^a   Hoshino, Nobuo ^a   Minouchi, Tokuzo ^a   Yamaji, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Acute renal failure; Bile acid; Cyclosporin; Intestinal absorption; Pharmacokinetics

Indexed keywords

BILE ACID; CYCLOSPORIN A; GENTAMICIN; URSODEOXYCHOLIC ACID; VERAPAMIL;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE FLOW; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CROSS REACTIVITY; INTESTINE ABSORPTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ABSORPTION; ADENOSINE TRIPHOSPHATE; ANIMALS; BILE; BILE ACIDS AND SALTS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; ENTEROCYTES; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENTAMICINS; IMMUNOSUPPRESSIVE AGENTS; JEJUNUM; KIDNEY FAILURE, ACUTE; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS; VERAPAMIL;

EID: 0034055968     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-100100862     Document Type: Article

References (22)

1. Ptachcinski RJ, Venkataramanan R, Burckart GJ: Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11:107, 1986.
2. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet, 24:472, 1993.
3. Gratwohl A, Speck B, Wenk M: Cyclosporine in human bone marrow transplantation: serum concentration, graft-versus-host disease and nephrotoxicity. Transplantation 36:40, 1983.
4. Lindholm A, Ringden O, Lonnqvist B: The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation 43:680, 1987.
5. Shibata N, Yamaji A, Park K, Tomoyoshi T, Sako H, Abe H, Kodama M, Nakane Y, Hodohara K, Hosoda S: A simple method for predicting the cyclosporin A erythrocyte-to-plasma distribution ratio in blood and its clinical assessment. Biol Pharm Bull 17:709, 1994.
6. Shaw LM, Bowers LB, Demers L, Freeman D, Moyer T, Sanghvi A, Seltman H, Venkataramanan R: Critical issue in cyclosporine monitoring: report of task force on cyclosporine monitoring. Clin Chem 33:1269, 1987.
7. Shibata N, Hoshino N, Minouchi T, Yamaji A, Park K, Tomoyoshi T, Abe H, Kodama M: Relationship between area under the concentration versus time curve of cyclosporin A, creatinine clearance, hematocrit value, and other clinical factors in Japanese renal transplant patients. Int J Clin Pharmacol Ther 36:202, 1998.
8. Schroeder TJ, Sridhar N, Pesce AJ, Alexander JW, First MR: Clinical correlations of cyclosporine-specific and -nonspecific assays in stable renal transplants, acute rejection, and cyclosporine nephrotoxicity. Ther Drug Monit 15:190, 1993.
9. Shibata N, Shimakawa H, Yamaji, A: Retrospective pharmacokinetic data analysis of cyclosporin A using routine monitoring data in renal transplant patients: consideration on its pharmacokinetic profiles and physiological factors during renal dysfunction. Jpn J Hosp Pharm 19:270, 1993.
10. Morimoto J, Shibata N, Hoshino N, Miniuchi T, Yamaji A, Kim CJ, Park KI, Kiso Y:Clinical utility of converting cyclosporine into tacrolimus in a living-related renal transplant patient with secondary nephrotic syndrome. Jpn J Ther Drug Monit 16:135, 1999.
11. Shibata N, Ohmae T, Hoshino N, Minouchi T, Yamaji A: Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in Rats. J Pharm Pharmacol 51:397, 1999.
12. Watkins PB: The barrier function of CYP3A4 and p-glycoprotein in the small bowel. Advanced Drug Delivery Reviews 29:161, 1997.
13. Barr WH, Reigelman S: Intestinal drug absorption and metabolism: comparison of methods and models to study physiological factors of in-vitro and in-vivo intestinal absorption. J Pharm Sci 59:154, 1970.
14. Yamaoka K, Nakagawa T, Uno T: Moment analysis for disposition kinetics of several cephalosporin antibiotics in rats. J Pharm Pharmacol 35:19, 1983.
15. Abbott Laboratories Diagnostic Division, TDx System Operation Manual, Abbott Laboratories, North Chicago, 1984.
16. Mehta MU, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Delamos B: Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 25:579, 1988.
17. Lindholm A, Henricsson S, Dahlqvist R: The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol 29:541, 1990.
18. Summerfield JA, Gollan JL, Billing BH: Synthesis of bile acid monosulfates by isolated perfused rat kidney. Biochem J 156:339, 1976.
19. Thomassen PA: Urinary bile acids in late pregnancy and in recurrent cholestasis of pregnancy. Eur J Clin Invest 9:425, 1979.
20. Bremmelgaard A: Bile acids in plasma of patients without kidney. Scand J Clin Lav Invest 43:603, 1983.
21. Cowen AE, Korman MG, Hofmann AF, Turcotte J, Carter JA: Radioimmunoassay of sulfated lithocholates. J Lipid Res 18: 698, 1977.
22. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Ren PS, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB: Role of intestnal P-glycoprotein (MDR1) in inter patient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248, 1997.